OncoMed is a clinical development-stage company focused on first-in-class monoclonal antibody therapeutics targeting cancer stem cells. The company has formed strategic alliances with Celgene, Bayer and GSK and has raised  approximately $622 million through venture capital and a 2013 IPO. We are excited to have Paul, a seasoned executive who has led OncoMed since 2006, chairs the Emerging Companies Section of BIO and serves on the board of the BayBio/CHI, share his thoughts with us.